Compounds & Therapies
Oral Minoxidil (Low-Dose)
Minoxidil is a potassium channel opener originally developed as an antihypertensive in the 1970s. The hair-growth side effect was noticed quickly; topical minoxidil was approved for androgenetic alopecia in 1988 and became the dominant…
Setipiprant
Setipiprant is a small-molecule antagonist of the prostaglandin D2 receptor 2 (DP2, also called CRTH2). It was originally developed as a potential treatment for asthma and allergic disorders due to PGD2's role in inflammatory responses. In 2012, a…
Topical Finasteride and Dutasteride
Oral finasteride (1 mg/day) and oral dutasteride (0.5 mg/day) are the most-evidenced medical therapies for male androgenetic alopecia. Both work by inhibiting 5-alpha reductase, the enzyme that converts testosterone to the more potent…
Practices & Lifestyle
Hair Transplant — FUE, FUT, and Robotic ARTAS
Hair transplantation moves hair from a donor area at the back and sides of the scalp (which is genetically resistant to DHT-mediated miniaturization) to a recipient area at the front and crown (which is not). The transplanted hairs retain their…
Ketoconazole Shampoo for AGA
Ketoconazole is an imidazole antifungal medication. As a topical shampoo (typically 2% ketoconazole in the United States as Nizoral, 1% as Nizoral A-D OTC, with various international generics), it is FDA-approved for treatment of seborrheic…
Pyrilutamide (KX-826)
As of mid-2026, Kintor reports that the pivotal Phase III stage in China met its primary endpoint with statistically significant and clinically meaningful efficacy in male AGA; a 52-week long-term safety Phase III also met endpoint. US Phase II positive. NDA planned in China.
Topical RU58841
RU58841 (also called PSK-3841) is a non-steroidal topical antiandrogen developed by Roussel Uclaf (later Sanofi) in the late 1980s and 1990s as a topical treatment for androgenetic alopecia (AGA, male and female pattern hair loss). It is a pure…